Cancilico
Cancilico is a pioneering company in AI-driven image-based diagnostics, focusing on revolutionizing the diagnosis and study of hematological cancers. Their flagship product, MyeloAID, is an AI software in development designed to automate the classification and counting of cells in bone marrow samples, aiming to deliver rapid and accurate myelograms. They also offer custom AI services for the pharmaceutical industry, including algorithm development for predicting drug success and identifying disease mutations, leveraging their expertise in AI-supported medical image analysis. Cancilico's platform supports data annotation, model development, and management, offering a user-friendly and expandable solution for medical research. The company is dedicated to improving patient outcomes and advancing medical research through enhanced accuracy and efficiency in diagnostics.
Cancilico
Cancilico is a pioneering company in AI-driven image-based diagnostics, focusing on revolutionizing the diagnosis and study of hematological cancers. Their flagship product, MyeloAID, is an AI software in development designed to automate the classification and counting of cells in bone marrow samples, aiming to deliver rapid and accurate myelograms. They also offer custom AI services for the pharmaceutical industry, including algorithm development for predicting drug success and identifying disease mutations, leveraging their expertise in AI-supported medical image analysis. Cancilico's platform supports data annotation, model development, and management, offering a user-friendly and expandable solution for medical research. The company is dedicated to improving patient outcomes and advancing medical research through enhanced accuracy and efficiency in diagnostics.